Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced that it will be extending its offered services with comprehensive inherited cardiovascular disease genetic test menu.
The newly validated tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for testing in both individual and familial settings. Two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy.
"Aviir's mission is to identify and prevent cardiovascular diseases, and subsequent deaths, through the best diagnostic means available," said Doug Harrington , M.D., CEO of Aviir. "To this end we've added a comprehensive list of inherited cardiovascular disease testing to our menu. This type of testing can be the difference between effective disease management and needless risk of sudden cardiac death. The novel approach Aviir has taken to identify disease-causing genetic variants allows for not only an unprecedented level of thoroughness (ie. 100% coverage of the disease-causing genes), but also for unmatched speed in returning results to physicians and patients."
Genetic testing can help determine a successful course of treatment for the patient, as well as identify any familial testing needs resulting from a positive result. In many instances the first indication that an individual is affected is sudden cardiac death, hence, testing is key to preventing a catastrophic event. This information can lead a patient to make successful lifestyle changes and pursue therapy to live a healthy and successful life despite the disease.
Study identifies DNA collisions driving genetic changes in cancer